NCT07246265 Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care
| NCT ID | NCT07246265 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Tours |
| Condition | Sickle Cell Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-03-05 |
| Primary Completion | 2028-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-03-05 with a primary completion date of 2028-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: Sickle cell disease is a genetic disorder of haemoglobin (which carries oxygen in red blood cells). The shape of sickle cell-patients' red blood cells is abnormal. Thus, red blood cells can be blocked in small vessels, responsible for painful crises due to a lack of downstream circulation. These crisis (acute vaso-occlusive crisis) require strong treatment based on morphine, and often require intensive care.However, treatment is often insufficiently effective. Patient can also experiment acute chest syndrome, a complication of vaso-occlusive crisis, which can be responsible for respiratory failure. In addition, patients with sickle cell disease frequently have kidney damage called sickle cell nephropathy, which in the early stages of the disease is responsible for renal hyperfiltration, meaning that the kidneys filter the blood more than necessary, with faster elimination of drugs. For example, it is known that higher doses of antibiotics must be used in these patients than in the general population for the same effectiveness. The hypothesis of the study is that morphine, a drug eliminated by kidneys, is underdosed in patients with sickle cell disease, which is responsible for the difficulties in achieving sufficient analgesia. Objective: To determine the glomerular filtration rate threshold for which it is necessary to prescribe higher doses of morphine in sickle cell patients with vaso-occlusive crisis. Methods: inclusion of 100 patients admitted to intensive care for an acute vaso-occlusive crisis or acute chest syndrome and receiving morphine. Within 24 hours of study inclusion, four morphine dosages will be performed, in parallel with a precise determination of the glomerular filtration rate by measuring the elimination rate of a tracer, 100% eliminated by the kidneys and injected at the start of the study. This tracer is iohexol, a contrast agent commonly used in radiology. Morphine underdosage will be interpretated regarding glomerular filtration rate. The effectiveness of analgesia and the amount of analgesics required will be also be analyzed. Outlook: At the end of this study, the investigators will be able to offer adapted doses of morphine for sickle cell patients in crisis, adapted to glomerular filtration rate, in the aim of personalizing analgesia.
Eligibility Criteria
Inclusion Criteria: * Patient ≥ 18 years old * Known homozygous sickle cell disease SS, SC, S-beta+, or S-beta0 * Admitted in an intensive care unit * Clinical diagnosis of vaso-occlusive crisis and/or acute chest syndrome * Receiving PCA treatment with morphine * Patient's consent for study participation and/or from a relative if case of patient's incapacity * Affiliation to social protection Exclusion Criteria: * Patient previously included in the study during a previous stay * Injection of iodinated contrast medium outside the scope of the study within 24 hours prior to inclusion, or scheduled within 9 hours following the scheduled time of iohexol injection * Contraindication to iohexol: known or suspected immediate or delayed hypersensitivity, thyrotoxicosis. * Patient undergoing morphine treatment or substitution treatment such as methadone or buprenorphine prior to hospitalization (having received morphine or a derivative regardless of the route of administration in the week prior to hospitalization). * Chronic liver disease likely to interfere with morphine metabolism (cirrhosis ) * Any condition that contraindicates the use of morphine according to the summary of product characteristics * Patients under legal protection * Pregnant or breastfeeding women Exclusion criteria : * Need for extrarenal epuration within 24 hours of inclusion
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07246265 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sickle Cell Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07246265 currently recruiting?
Yes, NCT07246265 is actively recruiting participants. Contact the research team at charlotte.salmon.gandonniere@gmail.com for enrollment information.
Where is the NCT07246265 trial being conducted?
This trial is being conducted at Tours, France, Créteil, France, Le Mans, France, Nantes, France and 2 additional locations.
Who is sponsoring the NCT07246265 clinical trial?
NCT07246265 is sponsored by University Hospital, Tours. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.